Dietary fish oil and the severity of symptoms in patients with systemic lupus erythematosus.
Quick navigation
Link to full study
http://www.ncbi.nlm.nih.gov/pubmed/1877851
Conclusion of this study
When individual outcome measures of the 17 patients who completed the full 34 week study were considered 14 who were receiving MaxEPA achieved useful or ideal status, whereas 13 receiving placebo were rated as worse or no change. The difference between the two types of capsule was statistically significant. No major side effects were noted, and it is suggested that dietary modification with additional marine oil may be a useful way of modifying disease activity in systemic lupus erythematosus.
Supplements analyzed in this study
Health conditions analyzed in this study
Functions related to this study
Body systems related to this study